Valuation: Protagonist Therapeutics, Inc.

Market Cap 8.72B 7.66B 7.13B 6.55B 12.3B 836B 12.47B 84.8B 33.12B 413B 32.73B 32.02B 1,427B P/E 2026 *
31.9x
P/E 2027 * -187x
Enterprise Value 8.14B 7.16B 6.66B 6.12B 11.49B 781B 11.64B 79.22B 30.94B 386B 30.57B 29.91B 1,333B EV / Sales 2026 *
15.4x
EV / Sales 2027 * 44.2x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -
1 day-0.40%
1 week+0.96%
Current month+10.59%
1 month+11.22%
3 months+37.61%
6 months+63.17%
Current year+55.21%
1 week 132
Extreme 132
139.92
1 month 118.27
Extreme 118.27
143.29
Current year 77
Extreme 77
143.29
1 year 50.48
Extreme 50.485
143.29
3 years 13.72
Extreme 13.72
143.29
5 years 6.91
Extreme 6.91
143.29
10 years 4.47
Extreme 4.47
143.29
Manager TitleAgeSince
Chief Executive Officer 69 01/12/2008
Director of Finance/CFO 52 18/04/2022
Chief Tech/Sci/R&D Officer - 01/04/2026
Director TitleAgeSince
Director/Board Member 69 01/12/2008
Chairman 71 19/03/2014
Director/Board Member 69 01/07/2016
Date Insider Type Main position Quantity % Market Cap.
6/23/26 A Fiscal year

Director

27,000 0.0420%
6/10/26 A Fiscal year

Director

27,000 0.0420%
5/29/26 A Fiscal year

Director

27,000 0.0420%
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%+0.96%+145.80%+621.83% 8.72B
-0.18%-0.96%-1.17%+10.70% 47.74B
-0.61%+4.26%+396.16%+647.20% 39.98B
0.00%+4.93%+11.81%+55.56% 36.23B
+2.48%+4.57%+7.05%-5.05% 35.59B
+0.62%+3.53%+5.41%+42.19% 27.91B
-0.17%+0.66% - - 16.71B
-2.00%+11.64%+31.71%+136.81% 16.45B
+0.15%-3.79%+2.45%+7.54% 13.21B
+1.82%+1.56%-9.75%-30.15% 12.93B
Average +0.17%+2.58%+65.50%+165.18% 25.55B
Weighted average by Cap. +0.23%+2.87%+76.70%+154.04%

Financials

2026 *2027 *
Net sales 530M 466M 434M 398M 748M 50.81B 758M 5.15B 2.01B 25.09B 1.99B 1.95B 86.72B 185M 162M 151M 139M 260M 17.7B 264M 1.8B 701M 8.74B 693M 678M 30.21B
Net income 279M 246M 229M 210M 394M 26.78B 399M 2.72B 1.06B 13.22B 1.05B 1.03B 45.71B -50.4M -44.31M -41.25M -37.88M -71.13M -4.83B -72.07M -490M -191M -2.39B -189M -185M -8.25B
Net Debt -574M -505M -470M -431M -810M -55.04B -821M -5.58B -2.18B -27.18B -2.15B -2.11B -93.93B -565M -496M -462M -424M -797M -54.16B -807M -5.49B -2.15B -26.74B -2.12B -2.07B -92.43B
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).
Employees
131
Date Price Change Volume
27/07/26 $135.56 -0.40% 416,781
24/07/26 $136.11 +0.50% 298,402
23/07/26 $135.43 -0.01% 605,784
22/07/26 $135.44 -2.08% 710,439
21/07/26 $138.31 +3.01% 580,567
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
135.56USD
Average target price
133.31USD
Spread / Average Target
-1.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTGX Stock